胃轻瘫:认识与治疗的转折点
胃轻瘫以胃排空延迟及恶心、呕吐、腹胀、餐后饱胀、早饱、腹痛为特征,病因包括糖尿病、术后、感染后及特发性。机制研究提示固有免疫失调及Cajal间质细胞和肠神经系统损伤是核心发病环节。闪烁显像和13C呼气试验是验证最充分的胃排空评估方法,治疗领域正迎来新进展。
要点
- 胃轻瘫定义基于胃排空延迟及相关症状,病因以糖尿病、术后、感染后及特发性为主。
- 闪烁显像和13C呼气试验是验证最充分的胃排空评估方法。
- 新治疗策略包括止吐药、促动力药和胃底松弛剂,内镜下幽门肌切开术短期有前景。
核心结论
- 固有免疫失调及Cajal间质细胞和肠神经系统损伤可能是胃轻瘫发病的核心环节。
- 内镜下幽门肌切开术短期对恶心和呕吐症状有前景,但需进一步对照试验和长期结局评估。
研究设计与样本
- 综述,汇总胃轻瘫的临床表现、诊断、机制和治疗进展。
主要发现
- 胃轻瘫临床表现和自然史因病因不同而异,伴随显著患病率和医疗资源使用。
- 糖尿病动物模型及人全层活检的机制研究显著推进了对该病的理解。
- 闪烁显像和13C呼气试验提供最验证的胃排空评估。
关键数值与推荐
- 胃轻瘫定义为胃排空延迟及恶心、呕吐、腹胀、餐后饱胀、早饱、腹痛症状。
- 较新治疗策略包括止吐药阿瑞匹坦、促动力药普芦卡必利和瑞拉莫林、胃底松弛剂阿考替胺和丁螺环酮。
临床怎么用
- 临床可依据病因评估胃轻瘫,并使用闪烁显像或13C呼气试验评估胃排空。
- 治疗可考虑较新止吐药、促动力药和胃底松弛剂,内镜下幽门肌切开术短期可改善恶心呕吐。
局限性
- 内镜下幽门肌切开术需进一步对照试验、识别幽门功能障碍合适亚组并评估长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gastroparesis is defined by delayed gastric emptying (GE) and symptoms of nausea, vomiting, bloating, postprandial fullness, early satiety and abdominal pain. Most common aetiologies include diabetes, postsurgical and postinfectious, but in many cases it is idiopathic. Clinical presentation and natural history vary by the aetiology. There is significant morbidity and healthcare utilisation associated with gastroparesis. Mechanistic studies from diabetic animal models of delayed GE as well as human full-thickness biopsies have significantly advanced our understanding of this disorder. An innate immune dysregulation and injury to the interstitial cells of Cajal and other components of the enteric nervous system through paracrine and oxidative stress mediators is likely central to the pathogenesis of gastroparesis. Scintigraphy and 13C breath testing provide the most validated assessment of GE. The stagnant gastroparesis therapeutic landscape is likely to soon see significant changes. Relatively newer treatment strategies include antiemetics (aprepitant), prokinetics (prucalopride, relamorelin) and fundic relaxants (acotiamide, buspirone). Endoscopic pyloromyotomy appears promising over the short term, especially for symptoms of nausea and vomiting. Further controlled trials and identification of the appropriate subgroup with pyloric dysfunction and assessment of long-term outcomes are essential. This review highlights the clinical presentation, diagnosis, mechanisms and treatment advancements for gastroparesis.
引用
- Grover M, Farrugia G, Stanghellini V, et al. Gastroparesis: a turning point in understanding and treatment. Gut. 2019. PMID: 31563877. doi:10.1136/gutjnl-2019-318712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。